Device advice - Issue 10
Hospital medical devices newsletter
Your update on PHARMAC’s Hospital Medical Devices programme
Issue 10 – 30 April 2015
In this issue:
PHARMAC is currently consulting on moving to the next stage of our hospital medical devices work – market share procurement.
On 14 April 2015 a discussion document was sent out to the sector and our stakeholders for feedback on our proposed approach to market share procurement for hospital medical devices.
For those of you who have not yet responded with your feedback on the document, we encourage you to please do so by 7 May 2015. You can access the discussion document here:
This next stage of activity would see us offering suppliers an assured portion of the market in return for competitive pricing and quality products. The feedback we receive will help us to refine that approach.
The discussion document proposes that wound care would be the first category to be considered for market share procurement. This is because we have substantially completed national contracting activity in this area and have enough information about the market, and clinical advice to enable us to run a market share approach, in some ranges of this category.
Our first national contracts for hospital medical devices took effect in February 2014. By 1 April 2015, PHARMAC had negotiated contracts for about 14,000 medical devices, covering approximately $44 million of expenditure. The savings to DHBs from PHARMAC’s contracted medical devices (this financial year and last) are estimated at $11.9 million over five years.
Sector input is essential for us to succeed in delivering the full benefits of a national management approach. We appreciate your continued engagement in our hospital medical devices work and look forward to receiving your feedback on this discussion document by 5pm 7 May 2015.
PHARMAC is currently seeking feedback on a proposal to list a range of interventional cardiology products supplied by Abbott Laboratories.
Around 350 interventional cardiology products are part of the proposed agreement, which would be listed in the Schedule and available for DHBs to purchase from 1 June 2015. This agreement would accompany three existing interventional cardiology product contracts PHARMAC has negotiated with BioExcel, Medtronic and Terumo.
The Abbott proposal has estimated total savings to DHBs of approximately $310,000 per annum, based on current usage.
Abbott would continue to provide educational services, tailored to suit the needs of individual DHB Hospitals as required.
We welcome feedback on this proposal, by Tuesday 12 May 2015.
We will regularly be updating all interested groups about the progress of the devices work programme. Feel free to circulate this newsletter to anyone you think might be interested in our hospital medical devices work.
You are welcome to contact us directly at any time with proposals, suggestions or concerns.
Email us: email@example.com or give us a call: 04 460 4990
You can find all of our medical devices listed as an Addendum to Section H of the Pharmaceutical Schedule.
For general information about our activity visit PHARMAC and hospital medical devices.
Last updated: 19 February 2019